JP2003533537A - タンパク質の誘導体化 - Google Patents

タンパク質の誘導体化

Info

Publication number
JP2003533537A
JP2003533537A JP2001585141A JP2001585141A JP2003533537A JP 2003533537 A JP2003533537 A JP 2003533537A JP 2001585141 A JP2001585141 A JP 2001585141A JP 2001585141 A JP2001585141 A JP 2001585141A JP 2003533537 A JP2003533537 A JP 2003533537A
Authority
JP
Japan
Prior art keywords
protein
derivatization
compound
reaction
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001585141A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003533537A5 (enExample
Inventor
グレゴリー グレゴリアディス
Original Assignee
リポクセン テクノロジーズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リポクセン テクノロジーズ リミテッド filed Critical リポクセン テクノロジーズ リミテッド
Publication of JP2003533537A publication Critical patent/JP2003533537A/ja
Publication of JP2003533537A5 publication Critical patent/JP2003533537A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01006—Catalase (1.11.1.6)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
JP2001585141A 2000-05-16 2001-05-14 タンパク質の誘導体化 Pending JP2003533537A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00304108.4 2000-05-16
EP00304108 2000-05-16
PCT/GB2001/002115 WO2001087922A2 (en) 2000-05-16 2001-05-14 Derivatisation of proteins in aqueous solution

Publications (2)

Publication Number Publication Date
JP2003533537A true JP2003533537A (ja) 2003-11-11
JP2003533537A5 JP2003533537A5 (enExample) 2008-06-05

Family

ID=8172993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001585141A Pending JP2003533537A (ja) 2000-05-16 2001-05-14 タンパク質の誘導体化

Country Status (8)

Country Link
US (1) US6962972B2 (enExample)
EP (1) EP1335931B1 (enExample)
JP (1) JP2003533537A (enExample)
AT (1) ATE313554T1 (enExample)
AU (1) AU2001258536A1 (enExample)
DE (1) DE60116137T2 (enExample)
ES (1) ES2256234T3 (enExample)
WO (1) WO2001087922A2 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007501889A (ja) * 2003-08-12 2007-02-01 リポクセン テクノロジーズ リミテッド タンパク質の誘導体化及び結合のためのシアル酸誘導体
JP2007501888A (ja) * 2003-08-12 2007-02-01 リポクセン テクノロジーズ リミテッド ポリシアル酸誘導体
JP2008510024A (ja) * 2004-08-12 2008-04-03 リポクセン テクノロジーズ リミテッド 分別
JP2008531764A (ja) * 2005-02-23 2008-08-14 リポクセン テクノロジーズ リミテッド タンパク質の誘導体化及び結合のための活性化シアル酸誘導体
JP2009544677A (ja) * 2006-07-25 2009-12-17 リポクセン テクノロジーズ リミテッド 顆粒球コロニー刺激因子の誘導体化
JP2013500375A (ja) * 2009-07-27 2013-01-07 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
JP2016113626A (ja) * 2009-07-27 2016-06-23 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3184551A1 (en) 2004-08-12 2017-06-28 Lipoxen Technologies Limited Sialic acid derivatives
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
EP2409995A3 (en) 2007-02-28 2012-08-15 Lipoxen Technologies Limited Reduction of endotoxin in polysialic acids
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
TR201908836T4 (tr) 2010-07-30 2019-07-22 Baxalta GmbH Oksim bağına yönelik nükleofilik katalizörler.
JP2014520094A (ja) 2011-05-27 2014-08-21 バクスター・インターナショナル・インコーポレイテッド 増加した半減期を有する治療用タンパク質およびそれを調製する方法
US9486507B2 (en) 2011-06-10 2016-11-08 Biogen Ma Inc. Pro-coagulant compounds and methods of use thereof
CN104271150A (zh) 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 嵌合因子viii多肽及其用途
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
JP6256882B2 (ja) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
AU2013204754C1 (en) 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
WO2013185113A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
CA2875247A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
CN104661674A (zh) 2012-07-11 2015-05-27 阿穆尼克斯运营公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
CN113817069A (zh) 2013-06-28 2021-12-21 比奥贝拉蒂治疗公司 具有xten的凝血酶可裂解连接子和其用途
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
HUE057005T2 (hu) 2013-09-25 2022-04-28 Bioverativ Therapeutics Inc Oszlopon történõ vírusinaktiváló eljárások
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
AU2015204646B2 (en) 2014-01-10 2020-08-27 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
WO2015130963A2 (en) 2014-02-27 2015-09-03 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
CU20170038A7 (es) 2014-09-26 2017-10-05 Bayer Pharma AG Derivados de adrenomedulina estabililzados especialmente útiles en el tratamiento y/o prevención de trastornos cardiovasculares, edematosos y/o inflamatorios
BR112017007765B1 (pt) 2014-10-14 2023-10-03 Halozyme, Inc Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
SG11201804666QA (en) 2015-12-03 2018-06-28 Baxalta Inc Factor viii with extended half-life and reduced ligand-binding properties
BR112018070459A2 (pt) 2016-04-04 2019-02-12 Shire Human Genetic Therapies, Inc. inibidor da c1 esterase conjugado e usos do mesmo
PE20210313A1 (es) 2018-03-28 2021-02-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
PL3793588T3 (pl) 2018-05-18 2025-09-01 Bioverativ Therapeutics Inc. Sposoby leczenia hemofilii a
KR20210027426A (ko) 2018-07-03 2021-03-10 브리스톨-마이어스 스큅 컴퍼니 Fgf21 제제
EP3986918A1 (en) 2019-06-18 2022-04-27 Bayer Aktiengesellschaft Adrenomedullin-analogues for long-term stabilization and their use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
GB9112212D0 (en) 1991-06-06 1991-07-24 Gregoriadis Gregory Pharmaceutical compositions
US5846951A (en) * 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007501888A (ja) * 2003-08-12 2007-02-01 リポクセン テクノロジーズ リミテッド ポリシアル酸誘導体
JP2007501889A (ja) * 2003-08-12 2007-02-01 リポクセン テクノロジーズ リミテッド タンパク質の誘導体化及び結合のためのシアル酸誘導体
JP2012082436A (ja) * 2004-08-12 2012-04-26 Lipoxen Technologies Ltd 電荷を有する多糖の分別
JP2008510024A (ja) * 2004-08-12 2008-04-03 リポクセン テクノロジーズ リミテッド 分別
JP2014169451A (ja) * 2004-08-12 2014-09-18 Lipoxen Technologies Ltd 電荷を有する多糖の分別
JP2008531764A (ja) * 2005-02-23 2008-08-14 リポクセン テクノロジーズ リミテッド タンパク質の誘導体化及び結合のための活性化シアル酸誘導体
JP2014114315A (ja) * 2006-07-25 2014-06-26 Lipoxen Technologies Ltd エリスロポエチンの多糖誘導体
US8981050B2 (en) 2006-07-25 2015-03-17 Lipoxen Technologies Limited N-terminal derivatisation of proteins with polysaccharides
US10300144B2 (en) 2006-07-25 2019-05-28 Lipoxen Technologies Limited N-terminal polysialylation
US8394921B2 (en) 2006-07-25 2013-03-12 Lipoxen Technologies Limited N-terminal derivatisation of proteins with polysaccharides
JP2013049675A (ja) * 2006-07-25 2013-03-14 Lipoxen Technologies Ltd Ｎ末端ポリシアリル化
JP2013100309A (ja) * 2006-07-25 2013-05-23 Lipoxen Technologies Ltd エリスロポエチンの多糖誘導体
JP2013121982A (ja) * 2006-07-25 2013-06-20 Lipoxen Technologies Ltd ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2013241446A (ja) * 2006-07-25 2013-12-05 Lipoxen Technologies Ltd ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2009544681A (ja) * 2006-07-25 2009-12-17 リポクセン テクノロジーズ リミテッド エリスロポエチンの多糖誘導体
JP2009544677A (ja) * 2006-07-25 2009-12-17 リポクセン テクノロジーズ リミテッド 顆粒球コロニー刺激因子の誘導体化
JP2015007062A (ja) * 2006-07-25 2015-01-15 リポクセン テクノロジーズ リミテッド Ｎ末端ポリシアリル化
JP2009544680A (ja) * 2006-07-25 2009-12-17 リポクセン テクノロジーズ リミテッド ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2015145400A (ja) * 2006-07-25 2015-08-13 リポクセン テクノロジーズ リミテッド ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2018039791A (ja) * 2006-07-25 2018-03-15 リポクセン テクノロジーズ リミテッド エリスロポエチンの多糖誘導体
JP2016128493A (ja) * 2006-07-25 2016-07-14 リポクセン テクノロジーズ リミテッド ポリサッカライドによるタンパク質のｎ末端誘導体化
US9492556B2 (en) 2006-07-25 2016-11-15 Lipoxen Technologies Limited N-terminal derivatisation of proteins with polysaccharides
JP2017018107A (ja) * 2006-07-25 2017-01-26 リポクセン テクノロジーズ リミテッド エリスロポエチンの多糖誘導体
US9789163B2 (en) 2006-07-25 2017-10-17 Lipoxen Technologies Limited N-terminal derivatisation of proteins with polysaccharides
US9795683B2 (en) 2009-07-27 2017-10-24 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
JP2018024882A (ja) * 2009-07-27 2018-02-15 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
JP2016113626A (ja) * 2009-07-27 2016-06-23 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
JP2013500375A (ja) * 2009-07-27 2013-01-07 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
US10772968B2 (en) 2009-07-27 2020-09-15 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
JP2022058911A (ja) * 2009-07-27 2022-04-12 バクサルタ インコーポレイテッド 非血液凝固タンパク質の糖ポリシアル酸化

Also Published As

Publication number Publication date
WO2001087922A3 (en) 2003-05-30
ATE313554T1 (de) 2006-01-15
ES2256234T3 (es) 2006-07-16
DE60116137D1 (de) 2006-01-26
US20030129159A1 (en) 2003-07-10
EP1335931A2 (en) 2003-08-20
AU2001258536A1 (en) 2001-11-26
DE60116137T2 (de) 2006-08-24
WO2001087922A2 (en) 2001-11-22
US6962972B2 (en) 2005-11-08
EP1335931B1 (en) 2005-12-21

Similar Documents

Publication Publication Date Title
JP2003533537A (ja) タンパク質の誘導体化
JP5586669B2 (ja) Ｎ末端ポリシアリル化
Jain et al. Polysialylated insulin: synthesis, characterization and biological activity in vivo
EP1090036B1 (en) Site specific protein modification by mutagenesis
EP0063109B1 (en) Therapeutically active compound and pharmaceutical composition containing the same
EP0973806B1 (en) Site protected protein modification
Morpurgo et al. Conjugates of peptides and proteins to polyethylene glycols
EA008505B1 (ru) Конъюгаты химически модифицированного гормона роста человека
JP2007501888A (ja) ポリシアル酸誘導体
JP2012116840A (ja) タンパク質ポリエチレングリコール（ｐｅｇ）複合体形成を増大させる方法
EP2837691B1 (en) Polymerized conjugates for biological applications
Zhang et al. Site-selective glycosylation of hemoglobin on Cys β93
Fehske et al. Direct demonstration of the highly reactive tyrosine residue of human serum albumin located in fragment 299–585
KR20060136463A (ko) 폴리에틸렌 글리콜(ｐｅｇ) 단백질 결합을 증가시키기 위한방법
Ladd et al. Reagents for the preparation of chromophorically labeled polyethylene glycol-protein conjugates
JPH05340948A (ja) 鶏卵抗体固定化担体およびその固定化方法
Veronese et al. Preparation and properties of monomethoxypoly (ethylene glycol)-modified enzymes for therapeutic applications
FR2496692A1 (fr) Procede de dosage de la peroxyde dismutase
Ito et al. Design and synthesis of a protein device that releases insulin in response to glucose concentration
JP2628310B2 (ja) 酵素の安定化方法
JPH05261281A (ja) 生理活性物質固定化担体とその製法
Mahbouba et al. Thiolation and disulphide cross-linking of insulin to form macromolecules of potential therapeutic value
Odajima et al. A chemical modification of myeloperoxidase and lactoperoxidase with 2‐(O‐methoxypolyethylene glycol)‐4, 6‐dichloro‐s‐triazine (activated PEG1)
CN118373870A (zh) 一种基于醛基巯基反应的蛋白偶联方法
JPH05345022A (ja) 生理活性物質固定化担体とその製法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100914

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110308